Systemische Sklerose

Allcock RJ, Forrest I, Corris PA et al. (2004) A study of the prevalence of systemic sclerosis in northeast England. Rheumatology (Oxford) 43: 596–602

Belch JJ (1991) Raynaud’s phenomenon: its relevance to scleroderma. Ann Rheum Dis 50 [Suppl 4]: 839–845

Binks M, Passweg JR, Furst D et al. (2001) Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease. Ann Rheum Dis 60: 577–584

Bryan C, Knight C, Black CM, Silman AJ (1999) Prediction of five-year survival following presentation with scleroderma: development of a simple model using three disease factors at first visit. Arthritis Rheum 42: 2660–2665

Clements PJ, Furst DE, Wong WK et al. (1999) High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum 42: 1194–1203

Clements PJ, Hurwitz EL, Wong WK et al. (2000) Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial. Arthritis Rheum 43: 2445–2454

DeMarco PJ, Weisman MH, Seibold JR et al. (2002) Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum 46: 2983–2989

Hachulla E, Gressin V, Guillevin L et al. (2005) Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 52: 3792–3800

Harris ML, Rosen A (2003) Autoimmunity in scleroderma: the origin, pathogenetic role, and clinical significance of autoantibodies. Curr Opin Rheumatol 15: 778–784

Keberle M, Tony HP, Jahns R et al. (2000) Assessment of microvascular changes in Raynaud’s phenomenon and connective tissue disease using colour doppler ultrasound. Rheumatology (Oxford) 39: 1206–1213

Korn JH, Mayes M, Matucci Cerinic M et al. (2004) Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 50: 3985–3993

Latsi PI, Wells AU (2003) Evaluation and management of alveolitis and interstitial lung disease in scleroderma. Curr Opin Rheumatol 15: 748–755

LeRoy EC, Black C, Fleischmajer R et al. (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15: 202–205

LeRoy EC, Medsger TA Jr (2001) Criteria for the classification of early systemic sclerosis. J Rheumatol 28: 1573–1576

Mayes MD, Lacey JV Jr, Beebe-Dimmer J et al. (2003) Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 48: 2246–2255

Pope JE, Bellamy N, Seibold JR et al. (2001) A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 44: 1351–1358

Reveille JD, Solomon DH (2003) Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. Arthritis Rheum 49: 399–412

Rubin LJ, Badesch DB, Barst RJ et al. (2002) Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346: 896–903

Sitbon O, Badesch DB, Channick RN et al. (2003) Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest 124: 247–254

Steen VD, Costantino JP, Shapiro AP, Medsger TA Jr (1990) Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med 113: 352–357